These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 25694060)

  • 1. Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes.
    Pacini G; Mari A; Fouqueray P; Bolze S; Roden M
    Diabetes Obes Metab; 2015 Jun; 17(6):541-545. PubMed ID: 25694060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents.
    Perry RJ; Cardone RL; Petersen MC; Zhang D; Fouqueray P; Hallakou-Bozec S; Bolze S; Shulman GI; Petersen KF; Kibbey RG
    Am J Physiol Endocrinol Metab; 2016 Aug; 311(2):E461-70. PubMed ID: 27406738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity.
    Theurey P; Thang C; Pirags V; Mari A; Pacini G; Bolze S; Hallakou-Bozec S; Fouqueray P
    Endocrinol Diabetes Metab; 2022 Nov; 5(6):e371. PubMed ID: 36239048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes.
    Henry RR; Smith SR; Schwartz SL; Mudaliar SR; Deacon CF; Holst JJ; Duan RY; Chen RS; List JF
    Diabetes Obes Metab; 2011 Sep; 13(9):850-8. PubMed ID: 21554520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology of imeglimin for the treatment of type 2 diabetes.
    Johansson KS; Brønden A; Knop FK; Christensen MB
    Expert Opin Pharmacother; 2020 Jun; 21(8):871-882. PubMed ID: 32108532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE; Matthews DR
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imeglimin preserves islet β-cell mass in Type 2 diabetic ZDF rats.
    Hallakou-Bozec S; Kergoat M; Moller DE; Bolze S
    Endocrinol Diabetes Metab; 2021 Apr; 4(2):e00193. PubMed ID: 33855202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.
    Derosa G; Ragonesi PD; Carbone A; Fogari E; Bianchi L; Bonaventura A; Romano D; Cicero AF; Maffioli P
    Diabetes Technol Ther; 2012 Jun; 14(6):475-84. PubMed ID: 22512264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period.
    Reilhac C; Dubourg J; Thang C; Grouin JM; Fouqueray P; Watada H
    Diabetes Obes Metab; 2022 May; 24(5):838-848. PubMed ID: 34984815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients.
    Pirags V; Lebovitz H; Fouqueray P
    Diabetes Obes Metab; 2012 Sep; 14(9):852-8. PubMed ID: 22519919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of insulin sensitivity, beta-cell function and glycaemic control on initiation of second-line glucose-lowering treatment in newly diagnosed type 2 diabetes.
    Rathmann W; Strassburger K; Bongaerts B; Bobrov P; Kuss O; Müssig K; Markgraf DF; Szendroedi J; Herder C; Roden M;
    Diabetes Obes Metab; 2017 Jun; 19(6):866-873. PubMed ID: 28127851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.
    Kjems LL; Holst JJ; Vølund A; Madsbad S
    Diabetes; 2003 Feb; 52(2):380-6. PubMed ID: 12540611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imeglimin mitigates the accumulation of dysfunctional mitochondria to restore insulin secretion and suppress apoptosis of pancreatic β-cells from db/db mice.
    Aoyagi K; Nishiwaki C; Nakamichi Y; Yamashita SI; Kanki T; Ohara-Imaizumi M
    Sci Rep; 2024 Mar; 14(1):6178. PubMed ID: 38485716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
    van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
    Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of imeglimin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials.
    Abdelhaleem IA; Salamah HM; Alsabbagh FA; Eid AM; Hussien HM; Mohamed NI; Ebada MA
    Diabetes Metab Syndr; 2021; 15(6):102323. PubMed ID: 34717136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial.
    Rissanen A; Howard CP; Botha J; Thuren T;
    Diabetes Obes Metab; 2012 Dec; 14(12):1088-96. PubMed ID: 22726220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in imeglimin response in subgroups of patients with type 2 diabetes stratified by data-driven cluster analysis: A post-hoc analysis of imeglimin clinical trial data.
    Hagi K; Kochi K; Watada H; Kaku K; Ueki K
    Diabetes Obes Metab; 2024 Sep; 26(9):3732-3742. PubMed ID: 38924336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function.
    Alba M; Ahrén B; Inzucchi SE; Guan Y; Mallick M; Xu L; O'Neill EA; Williams-Herman DE; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2013 Dec; 15(12):1101-10. PubMed ID: 23782502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes.
    Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
    Diabet Med; 2012 Dec; 29(12):1515-23. PubMed ID: 22540883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes.
    Vuylsteke V; Chastain LM; Maggu GA; Brown C
    Drugs R D; 2015 Sep; 15(3):227-32. PubMed ID: 26254210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.